Soft-tissue @entity242 are characterized by the development of disease recurrence in a distinct subgroup of @entity1 . Despite intense efforts in applying multimodal treatment, the risk of local recurrence or distant metastases remains a considerable threat to @entity1 with soft-tissue @entity242 . This review focuses on the efforts aimed at defining local and systemic @entity5 extent at the level of minimal @entity41 cell detection. Examination of @entity41 in soft-tissue @entity242 has experienced a significant boost from the definition of fusion transcripts resulting from stable chromosomal translocations. The sensitivity and exclusive specificity of the reverse-transcription polymerase chain reaction (RT-PCR) protocols have given insights into @entity5 cell residues in nearly all body compartments. The accumulated data demonstrates that even after oncologic resections most @entity1 will still harbor a significant @entity5 burden. Clinical concepts arising out of these new data are under way. One of these concepts is the targeting of the fusion transcript for therapy. However, this approach is still restricted to the experimental setting. The development of clinical applications remains a challenging task, requiring the treatment of as many @entity1 as possible in centers specializing in all of the affected disciplines.

@entity41 in soft-tissue XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'residual disease (MRD) tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'sarcomas']
@entity242 :: (MESH:D012509,Disease) :: ['sarcomas']
